The New Drug Conditional Approval Process in China: Challenges and Opportunities
Authors:
- 1 May 2017
- journal article
- review article
- Published by Elsevier in Clinical Therapeutics
- Vol. 39 (5) , 1040-1051
Abstract
No abstract availableKeywords
This publication has 3 references indexed in Scilit:
- Characteristics and follow‐up of postmarketing studies of conditionally authorized medicines in the EUBritish Journal of Clinical Pharmacology, 2016
- Development of chidamide for peripheral T-cell lymphoma, the first orphan drug approved in ChinaIntractable & Rare Diseases Research, 2016
- Accelerated Approval of Oncology Products: The Food and Drug Administration ExperienceJNCI: Journal of the National Cancer Institute, 2011